Zacks Research Predicts Neogen’s Q2 Earnings (NASDAQ:NEOG)

Neogen Co. (NASDAQ:NEOG) – Research analysts at Zacks Research reduced their Q2 2027 earnings per share estimates for shares of Neogen in a report released on Wednesday, June 4th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.12 per share for the quarter, down from their previous forecast of $0.13. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share.

Neogen (NASDAQ:NEOG) last released its quarterly earnings data on Wednesday, April 9th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The business had revenue of $221.00 million during the quarter, compared to analyst estimates of $225.27 million. During the same quarter in the prior year, the company posted $0.12 earnings per share. The company’s revenue was down 3.4% on a year-over-year basis.

A number of other research firms have also recently commented on NEOG. Piper Sandler decreased their price objective on Neogen from $6.40 to $5.00 and set a “neutral” rating on the stock in a report on Tuesday, April 22nd. Guggenheim decreased their price objective on Neogen from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, April 10th.

Neogen Trading Up 6.0%

NEOG opened at $5.52 on Monday. Neogen has a one year low of $3.87 and a one year high of $18.58. The stock has a market capitalization of $1.20 billion, a PE ratio of -2.52 and a beta of 1.84. The business’s 50 day moving average price is $5.78 and its 200 day moving average price is $9.29. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.46 and a current ratio of 3.77.

Insiders Place Their Bets

In other news, Director Aashima Gupta purchased 16,000 shares of the firm’s stock in a transaction on Monday, May 12th. The shares were bought at an average cost of $6.25 per share, for a total transaction of $100,000.00. Following the completion of the purchase, the director now directly owns 21,917 shares of the company’s stock, valued at approximately $136,981.25. This trade represents a 270.41% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO John Patrick Moylan purchased 10,000 shares of the firm’s stock in a transaction on Thursday, April 10th. The shares were purchased at an average price of $5.07 per share, for a total transaction of $50,700.00. Following the completion of the purchase, the chief accounting officer now directly owns 10,000 shares of the company’s stock, valued at $50,700. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 83,500 shares of company stock worth $431,525 over the last ninety days. Corporate insiders own 1.13% of the company’s stock.

Institutional Trading of Neogen

Large investors have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Neogen during the fourth quarter worth $2,744,000. Dimensional Fund Advisors LP increased its position in shares of Neogen by 24.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 6,939,984 shares of the company’s stock worth $84,254,000 after acquiring an additional 1,345,056 shares during the period. Norges Bank purchased a new stake in shares of Neogen during the fourth quarter worth $212,171,000. Vanguard Group Inc. increased its position in shares of Neogen by 9.8% during the fourth quarter. Vanguard Group Inc. now owns 21,637,251 shares of the company’s stock worth $262,676,000 after acquiring an additional 1,928,491 shares during the period. Finally, Private Advisor Group LLC increased its position in shares of Neogen by 135.3% during the fourth quarter. Private Advisor Group LLC now owns 67,298 shares of the company’s stock worth $817,000 after acquiring an additional 38,703 shares during the period. Hedge funds and other institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.